Compare ATNM & CNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATNM | CNF |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7M | 34.6M |
| IPO Year | 2013 | 2018 |
| Metric | ATNM | CNF |
|---|---|---|
| Price | $0.80 | $2.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 94.4K | 36.2K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $90,000.00 | N/A |
| Revenue This Year | N/A | $252.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.11 | N/A |
| 52 Week Low | $0.74 | $0.37 |
| 52 Week High | $1.81 | $24.00 |
| Indicator | ATNM | CNF |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 42.91 |
| Support Level | N/A | $2.12 |
| Resistance Level | $1.38 | $3.49 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 28.05 | 23.16 |
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.